German pharmaceutical and life sciences company Bayer AG (ETR:BAYN) (OTC:BAYRY) and its subsidiary BlueRock Therapeutics LP, a clinical stage cell therapy company, on Tuesday reported positive 36-month data from a Phase I clinical trial of bemdaneprocel, an investigational cell therapy for Parkinson's disease.

The findings were presented on 6 October at the International Congress of Parkinson's Disease and Movement Disorders.

The therapy continued to demonstrate a favourable safety profile, with no treatment- or surgery-related adverse events reported. Imaging results indicate that transplanted cells remained viable and engrafted in the brain following the discontinuation of immunosuppression at 12 months.

Motor function outcomes remained stable compared to 24 months and continued to show improvement from baseline. In the high-dose cohort, participants recorded a mean reduction of 17.9 points on the MDS-UPDRS Part III "OFF"-medication score, compared with a 13.5-point reduction in the low-dose cohort.

Patients receiving the higher dose also experienced an average one-hour increase in "Good ON" time and nearly a one-hour reduction in "OFF" time, as measured by the Parkinson's Disease Diary. Both cohorts continue to participate in the long-term Continued Evaluation Study.